Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Special Issues
August 2016, Vol 7, No7, Special Issue: Payers' Perspectives in Oncology
August 2016, Vol 7, No 7, Special Issue: Payers’ Perspectives in Oncology
Extending Letrozole Therapy Beyond 5 Years in Early Breast Cancer Reduces Recurrence
By
Phoebe Starr
Breast Cancer
,
Solid Tumors
August 2016, Vol 7, No 7, Special Issue: Payers’ Perspectives in Oncology
Extending aromatase inhibitor therapy with letrozole for an additional 5 years beyond standard treatment with letrozole improved disease-free survival (DFS) and reduced the rate of new contralateral breast cancer in postmenopausal women with estrogen receptor (ER)-positive breast cancer.
Read Article
Atezolizumab Could Be Start of “Seismic Shift” in Metastatic Bladder Cancer Therapy
By
Wayne Kuznar
Bladder Cancer
,
Solid Tumors
August 2016, Vol 7, No 7, Special Issue: Payers’ Perspectives in Oncology
Atezolizumab (Tecentriq) shows promise as primary therapy in patients with cisplatin-ineligible, locally advanced metastatic urothelial (bladder) cancer, according to data from the IMvigor210 study presented at ASCO 2016.
Read Article
Gene-Expression Signature Validated as Prognostic Marker in Stage II Colon Cancer
By
Alice Goodman
Personalized Medicine
August 2016, Vol 7, No 7, Special Issue: Payers’ Perspectives in Oncology
A gene-expression signature assay called ColDx (Almac Diagnostics) successfully identified high-risk patients with stage II colon cancer who would benefit from chemotherapy, according to results of a new, prospective analysis of the previously published phase 3 Alliance C9581 clinical trial.
Read Article
A New Paradigm Matching Targeted Therapy to Molecular Alterations Independent of Tumor Type
By
Phoebe Starr
Personalized Medicine
,
Targeted Therapy
August 2016, Vol 7, No 7, Special Issue: Payers’ Perspectives in Oncology
Ongoing clinical trials at academic centers around the country are testing a new strategy of matching available targeted therapies to molecular abnormalities in tumors instead of treating the cancer site.
Read Article
In the Literature - August 2016
In the Literature
August 2016, Vol 7, No 7, Special Issue: Payers’ Perspectives in Oncology
Read Article
How to Reduce Financial Toxicity in Patients with Cancer
By
Chase Doyle
Financial Toxicity
,
Value in Oncology
August 2016, Vol 7, No 7, Special Issue: Payers’ Perspectives in Oncology
In addition to affecting patient well-being and quality of life, financial toxicity has been shown to worsen survival outcomes because of nonadherence to drug therapy. Although policy interventions, improvements in benefit designs, and adjustments to reimbursement may help reduce costs for patients in the long-term, immediate changes are needed to alleviate financial burden, said Yousuf Zafar, MD, MHS, of the Duke Cancer Institute, Durham, NC, at ASCO 2016.
Read Article
Transition from Branded to Generic Cancer Drugs Significantly Increases Treatment Cost-Effectiveness
By
Chase Doyle
Value in Oncology
August 2016, Vol 7, No 7, Special Issue: Payers’ Perspectives in Oncology
An economic analysis of oncology regimens that were previously evaluated in trials conducted by the Canadian Cancer Society Research Institute has shown that the transition from branded to generic drug costs has a considerable impact on the cost-effectiveness and cost-utility of treatment.
Read Article
Aggressive End-of-Life Care Continues to Be Offered to Younger Patients with Cancer
By
Phoebe Starr
End-of-Life Care
,
Value in Oncology
,
Policies & Guidelines
August 2016, Vol 7, No 7, Special Issue: Payers’ Perspectives in Oncology
Aggressive end-of-life care for patients with terminal cancer and other illnesses is costly and not recommended. ASCO recommends that patients with terminal cancer should receive palliative care rather than interventions that do not prolong life but do add to suffering.
Read Article
The Oncology Drug Pipeline Shows No Evidence of Slowing Down
By
Wayne Kuznar
Emerging Therapies
,
Personalized Medicine
August 2016, Vol 7, No 7, Special Issue: Payers’ Perspectives in Oncology
Oral and poster presentations of several promising agents in early- and late-phase clinical trials dotted the program at ASCO 2016. The presentations included studies with positive findings associated with many investigational therapies, including first-in-class therapies such as chimeric antigen receptor (CAR) T-cells for the treatment of patients with B-cell malignancies or acute myeloid leukemia (AML); a vaccine (galinpepimut-S) for the treatment of patients with AML; and a chimeric monoclonal antibody against claudin 18.2 for the treatment of patients with advanced gastric cancers.
Read Article
“Smart Bomb” First-in-Class Drug Rova-T Promising Novel Therapy for Small-Cell Lung Cancer
By
Phoebe Starr
Emerging Therapies
,
Personalized Medicine
August 2016, Vol 7, No 7, Special Issue: Payers’ Perspectives in Oncology
The first-in-class antibody-drug conjugate rovalpituzumab tesirine (Rova-T) may be a new treatment option for patients with small-cell lung cancer (SCLC), which has a very poor prognosis and few treatment options. Rova-T is particularly promising in SCLC tumors that overexpress the delta-like (DLL) 3 protein, according to first-in-human study results presented at ASCO 2016.
Read Article
Page 2 of 3
1
2
3
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma